{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:16:30Z","timestamp":1771884990694,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:00:00Z","timestamp":1436227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","award":["not available"],"award-info":[{"award-number":["not available"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This follow\u2010up extension of a randomised phase <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content> study assessed differences in long\u2010term outcomes between bortezomib\u2010thalidomide\u2010dexamethasone (<jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content>) and <jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content>\u2010cyclophosphamide (<jats:styled-content style=\"fixed-case\">VTDC<\/jats:styled-content>) induction therapy in multiple myeloma. Newly diagnosed patients (<jats:italic>n\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>98) were randomised 1:1 to intravenous bortezomib (1\u00b73\u00a0mg\/m<jats:sup>2<\/jats:sup>; days 1, 4, 8, 11), thalidomide (100\u00a0mg; days 1\u201321), and dexamethasone (40\u00a0mg; days 1\u20134, 9\u201312), with\/without cyclophosphamide (400\u00a0mg\/m<jats:sup>2<\/jats:sup>; days 1, 8), for four 21\u2010day cycles before stem\u2010cell mobilisation\/transplantation. After a median follow\u2010up of 64\u00b78\u00a0months, median time\u2010to\u2010next therapy was 51\u00b78 and 47\u00b79\u00a0months with <jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">VTDC<\/jats:styled-content>, respectively. Type of subsequent therapy was similar in both arms. After adjusting for asymmetric censoring, median time to progression was not significantly different between <jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">VTDC<\/jats:styled-content> [35\u00b77 vs. 34\u00b75\u00a0months; Hazard ratio (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) 1\u00b726, 95% confidence interval: 0\u00b776\u20132\u00b709; <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0\u00b7370]. Five\u2010year survival was 69\u00b71% and 65\u00b73% with <jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">VTDC<\/jats:styled-content>, respectively. When analysed by minimal residual disease (<jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>) status, overall survival was longer in <jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>\u2010negative <jats:italic>versus <\/jats:italic><jats:styled-content style=\"fixed-case\">MRD<\/jats:styled-content>\u2010positive patients with bone marrow\u2010confirmed complete response (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> 3\u00b766, <jats:italic>P\u00a0<\/jats:italic>=<jats:italic>\u00a0<\/jats:italic>0\u00b70318). <jats:styled-content style=\"fixed-case\">VTD<\/jats:styled-content> induction followed by transplantation provides long\u2010term disease control and, consistent with the primary analysis, there is no additional benefit from adding cyclophosphamide. This study was registered at ClinicalTrials.gov (<jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>00531453).<\/jats:p>","DOI":"10.1111\/bjh.13582","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T02:45:15Z","timestamp":1436323515000},"page":"344-354","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5\u2010year follow\u2010up"],"prefix":"10.1111","volume":"171","author":[{"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"c\/o First Department of Medicine Centre for Oncology, Haematology and Palliative Care Wilhelminen Cancer Research Institute Wilhelminenspital Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"Landeskrankenhaus Universit\u00e4tsklinik f\u00fcr Innere Medizin III Salzburg Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Masszi","sequence":"additional","affiliation":[{"name":"Department of Haematology and Stem Cell Transplantation St Istv\u00e1n and St L\u00e1szl\u00f3 Hospital Budapest Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"First Faculty of Medicine First Medical Department Clinical Department of Haematology Charles University in Prague Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[{"name":"Institute of Haematology Assuta Medical Centre Tel\u2010Aviv Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology FN Ostrava and Faculty of Medicine Ostrava Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dmoszynska","sequence":"additional","affiliation":[{"name":"Medical University of Lublin Lublin Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n M\u00e9dica Aplicada (CIMA) Cl\u00ednica Universidad de Navarra Pamplona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda\u2010Bel\u00e9n","family":"Vidriales","sequence":"additional","affiliation":[{"name":"IBMCC (USAL\u2010CSIC) Hospital Universitario Salamanca CIC Salamanca Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graca","family":"Esteves","sequence":"additional","affiliation":[{"name":"Hospital de Dia de Hematologia Hospital de Santa Maria Lisbon Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Stoppa","sequence":"additional","affiliation":[{"name":"Institut Paoli\u2010Calmettes Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Don","family":"Robinson","sequence":"additional","affiliation":[{"name":"Janssen Global Services LLC Raritan NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini","family":"Chaturvedi","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Ataman","sequence":"additional","affiliation":[{"name":"Division of Janssen\u2010Cilag Limited Janssen Research &amp; Development High Wycombe UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Enny","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaibao","family":"Feng","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development LLC Spring House PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development Division of Janssen Pharmaceutica NV Beerse Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Viterbo","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Onco\u2010Hematologia Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil Entidade P\u00fablica Empresarial (IPOPFG, EPE) Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,7,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0004"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61424-9"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408898"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1182\/blood.V122.21.2090.2090","article-title":"Persistent improvement in clinical outcomes with bortezomib\u2010thalidomide\u2010dexamethasone vs thalidomide\u2010dexamethasone incorporated into double autologous transplantation for multiple myeloma: an updated analysis of phase 3 GIMEMA\u2010MMY\u20103006 study","volume":"122","author":"Cavo M.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1182\/blood.V124.21.197.197","article-title":"Superior efficacy of VTD over VCD as induction therapy for autotransplantation\u2010eligible, newly diagnosed, myeloma patients","volume":"124","author":"Cavo M.","year":"2014","journal-title":"Blood"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.05.009"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-334755"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-422683"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.07.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12946"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5137"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0042"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-550020"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573733"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05045.x"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355081"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.1967"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.217"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.2119"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271676"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408922"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V120.21.334.334","article-title":"Maintenance therapy after stem\u2010cell transplantation for multiple myeloma with bortezomib\/thalidomide vs. thalidomide vs. alfa2b\u2010interferon: Final results of a phase III PETHEMA\/GEM randomized trial","volume":"120","author":"Rosi\u00f1ol L.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"e_1_2_8_30_1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.V122.21.404.404","article-title":"Bortezomib induction and maintenance treatment improves survival in patients with newly diagnosed multiple myeloma: Extended follow\u2010up of the HOVON\u201065\/GMMG\u2010HD4 trial","volume":"122","author":"Sonneveld P.","year":"2013","journal-title":"Blood"},{"key":"e_1_2_8_31_1","first-page":"131","article-title":"Quantitative serum free light chain assay\u2010analytical issues","volume":"30","author":"Tate J.","year":"2009","journal-title":"The Clinical Biochemist Reviews"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13582","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13582","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.13582","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T18:12:49Z","timestamp":1696356769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,7]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/bjh.13582"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13582","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,7]]},"assertion":[{"value":"2015-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-07-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}